Abstract:In this issue, Mattano et al. report on the development of osteonecrosis among patients with acute lymphoblastic leukemia (ALL) treated in the Children's Oncology Group trial AALL0232 [1]. Apart from analyzing the incidence and risk factors for osteonecrosis, the authors also analyze the impact of osteonecrosis on event-free survival (EFS) and overall survival (OS). Surprisingly, both EFS and OS were superior among patients who developed osteonecrosis compared to those who did not. Osteonecrosis was seen predominately among patients ≥10 years of age, constituting 93% of the study cohort, a demographic associated with poor prognosis in childhood ALL. Furthermore, the study underscored that both Capizzi methotrexate and dexamethasone were associated with an increased risk of osteonecrosis. Despite the lack of previous association of these two agents with superior survival, patients who developed osteonecrosis exhibited a survival advantage [2]. Thus, the question arises: How does osteonecrosis lead to improved survival outcomes? The answer to this may partly, if not fully, lies in the analysis methodology and could be attributed to immortal time bias (ITB) or guaranteed time bias [3, 4]. ITB is indeed a primary concern of such analyses because patients who experience toxic death, progression, or relapse earlier are not expected to develop delayed toxicities such as osteonecrosis. Conversely, patients who remain in the study for a long duration have more time to experience toxicity. In the present study, the median time to osteonecrosis was 455 days. This suggests that within this timeframe, patients certainly cannot experience certain events such as death. Consequently, this period can be regarded as an immortal time for patients in this group, directly influencing the analysis of EFS and OS. In addition, the study highlights a lower cumulative incidence of relapse (CIR) and a longer median time to relapse among patients with osteonecrosis compared to those without osteonecrosis. Again, CIR in the osteonecrosis group may be confounded by the absence of induction/remission deaths, which are competing events. The difference in time to relapse can be explained by the fact that patients who experience relapse early during therapy may not survive long enough to develop osteonecrosis due to high-risk nature of relapse.

A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group

Genetic polymorphism of vitamin D receptors and plasminogen activator inhibitor-1 and osteonecrosis risk in childhood acute lymphoblastic leukemia

MDR1(ABCB1) Gene Polymorphisms Associated with Steroid-Induced Osteonecrosis of Femoral Head in Systemic Lupus Erythematosus.

Genetic risk factors for glucocorticoid-induced osteonecrosis: a meta-analysis

Polymorphisms in the Glucocorticoid Receptor Gene and Associations with Glucocorticoid-Induced Avascular Osteonecrosis of the Femoral Head.

Significant associations of PAI-1 genetic polymorphisms with osteonecrosis of the femoral head

Genetic Biomarkers to Identify the Risk of Osteonecrosis in Children with Acute Lymphoblastic Leukemia

Genetic polymorphisms in plasminogen activator inhibitor-1 predict susceptibility to steroid-induced osteonecrosis of the femoral head in Chinese population

Genome-wide study identifies novel genes associated with bone toxicities in children with acute lymphoblastic leukaemia

Association of plasminogen activator inhibitor-1 genotype with avascular osteonecrosis in steroid-treated renal allograft recipients

A Functional Polymorphism in the Paired Basic Amino Acid-Cleaving Enzyme 4 Gene Confers Osteoarthritis Risk in a Population of Eastern China

The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia

Investigation of the Relationship Between Fok1 and Col1A1 Gene Polymorphisms and Development of Treatment-Related Bone Complications in Children with Acute Lymphoblastic Leukemia

Association of a polymorphism in PON-1 gene with steroid-induced osteonecrosis of femoral head in Chinese Han population

Early-Onset Osteoporosis: Molecular Analysis in Large Cohort and Focus on the PLS3 Gene

Association between genetic polymorphisms and osteonecrosis in steroid treatment populations: a detailed stratified and dose-response meta-analysis

Genetic susceptibility and late bone outcomes in childhood acute lymphoblastic leukemia survivors

Age At Onset-Dependent Presentations Of Premature Hip Osteoarthritis, Avascular Necrosis Of The Femoral Head, Or Legg-Calve-Perthes Disease In A Single Family, Consequent Upon A P.Gly1170ser Mutation Of Col2a1

Relationship between the Apolipoprotein AI, B gene polymorphism and the risk of non-traumatic osteonecrosis

Relationship between post-SARS osteonecrosis and PAI-1 4G/5G gene polymorphisms

Mitigating immortal-time bias: exploring osteonecrosis and survival in pediatric ALL - AALL0232 trial insights